Stimulation of haemopoiesis and protection of mice against radiation injury by synthetic analogues of muramyldipeptide incorporated in liposomes
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9637362
DOI
10.1016/s0192-0561(98)00003-4
PII: S0192-0561(98)00003-4
Knihovny.cz E-resources
- MeSH
- Acetylmuramyl-Alanyl-Isoglutamine administration & dosage analogs & derivatives pharmacology MeSH
- Adjuvants, Immunologic administration & dosage pharmacology MeSH
- Colony-Forming Units Assay MeSH
- Radiation Injuries, Experimental prevention & control MeSH
- Glycopeptides administration & dosage pharmacology MeSH
- Hematopoiesis drug effects radiation effects MeSH
- Liposomes MeSH
- Mice, Inbred C57BL MeSH
- Mice, Inbred CBA MeSH
- Mice MeSH
- Radiation-Protective Agents administration & dosage pharmacology MeSH
- Gamma Rays MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetylmuramyl-Alanyl-Isoglutamine MeSH
- Adjuvants, Immunologic MeSH
- Glc-(1-4)-norMurNAc-Abu-isoGln MeSH Browser
- GlcNstearoyl-(1-4)-norMurNAc-Abu-isoGln MeSH Browser
- Glycopeptides MeSH
- Liposomes MeSH
- Radiation-Protective Agents MeSH
Protection from undesirable effects of radiotherapy or chemotherapy, primarily from myelosuppression, remains still a crucial problem to be studied. Attention has been therefore paid to various immunomodulatory agents that through the monocyte/macrophage system induced production of cytokines, which can induce and operate restoration of haemopoiesis and thus act radioprotectively. Some synthetic analogues of MDP free of undesirable side-effects, were synthesized in the Czech Republic. Lipophilic beta-D-GlcNstearoyl-(1- > 4)-norMurNAc-L-Abu-D-isoGln (DDD-St) was designed to be easily entrapped into liposomes and this liposomal DDD-St protected efficiently mice against irradiation, when administered i.p., i.v. or s.c. 24 h prior to lethal irradiation (survival rate in the range of 30-80% compared with 0% in control). Especially the subcutaneous application of liposomal DDD-St was very efficient. The parameters characteristic of recovery of haemopoiesis in bone marrow on day 10 after 6.5 Gy irradiation were significantly improved in comparison with the controls. Very high radioprotective effect of s.c. administered liposomal DDD-St can be explained (together with induction of haemopoiesis) by an effective and long-lasting activation of nonspecific immunity, which is able to withhold an onset of septicemia in early days after irradiation. In conclusion, the liposomal DDD-St should be therapeutically beneficial in moderating the haemopoietic damage, which is an undesirable effect of radiotherapy or chemotherapy.
References provided by Crossref.org